Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for cardiovascular disease
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy. However, the strategy of ticagrelor monotherapy has not been exclusively evaluated in patients with acute coronary syndromes (ACS).To determine whether switching to ticagrelor monotherapy after 3 (...) with ticagrelor-based 12-month DAPT (HR, 0.56 [95% CI, 0.34 to 0.91]; P = .02). The incidence of major adverse cardiac and cerebrovascular events was not significantly different between the ticagrelor monotherapy after 3-month DAPT group (2.3%) vs the ticagrelor-based 12-month DAPT group (3.4%) (HR, 0.69 [95% CI, 0.45 to 1.06]; P = .09).Among patients with acute coronary syndromes treated with drug-eluting stents, ticagrelor monotherapy after 3 months of dual antiplatelet therapy, compared with ticagrelor
Strategies For Risk Reduction and Management of Older Adults With CardiovascularDisease During the COVID-19 Pandemic Strategies For Risk Reduction and Management of Older Adults With CardiovascularDisease During the COVID-19 Pandemic - American College of Cardiology ') Search All Types Search or Menu . This article was authored by Nicole M. Orr, MD, FACC , and the Geriatric Cardiology Council. Share via: Clinical Topics: Keywords: Aged, SARS Virus, Angiotensin Receptor Antagonists (...) , Hydroxychloroquine, Mineralocorticoid Receptor Antagonists, Caregivers, Angiotensin-Converting Enzyme Inhibitors, COVID-19, Coronavirus, Coronavirus Infections, Neprilysin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Neprilysin, Chloroquine, Subacute Care, Social Isolation, Skilled Nursing Facilities, CardiovascularDiseases > > Strategies For Risk Reduction and Management of Older Adults With CardiovascularDisease During the COVID-19 Pandemic Heart House 2400 N Street NW Washington, DC 20037 Phone: , ext
Covid-19 and cardiovasculardisease. Guideline: Diagnosis and management of cardiovasculardisease during the covid-19 pandemicPublished by the European Society of Cardiology.This summary is based on the version published on 21 April 2020 (https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance).Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing
Variations between women and men in risk factors, treatments, cardiovasculardisease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Some studies, mainly from high-income countries (HICs), report that women receive less care (investigations and treatments) for cardiovasculardisease than do men and might have a higher risk of death. However, very few studies systematically report risk factors, use of primary or secondary (...) prevention medications, incidence of cardiovasculardisease, or death in populations drawn from the community. Given that most cardiovasculardisease occurs in low-income and middle-income countries (LMICs), there is a need for comprehensive information comparing treatments and outcomes between women and men in HICs, middle-income countries, and low-income countries from community-based population studies.In the Prospective Urban Rural Epidemiological study (PURE), individuals aged 35-70 years from urban
Position Statement on Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic CardiovascularDisease During the COVID-19 Pandemic 1 Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic CardiovascularDisease During the COVID-19 Pandemic: A Position Statement by the Cardiac Society of Australia and New Zealand Stephen J Nicholls 1 , Mark Nelson 2 , Carolyn Astley 3 , Tom Briffa 4 , Alex Brown 5 , Robyn Clark 3 , David Colquhoun 6 , Robyn Gallagher (...) care across the world. In addition to the described cardiovasculardisease (CVD) complications of COVID-19, including myocarditis, myocardial injury, arrhythmia and thromboembolism, the pandemic has additional implications for the management of the patient with established atherosclerotic CVD. In particular, it provides challenges for the use and introduction of secondary prevention measures. This position statement provides recommendations for effective delivery of secondary prevention strategies
Abstract Introduction: The Coronavirus-19 disease (COVID-19) pandemic is caused by acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Pre-existing cardiovasculardisease (CVD) increases the morbidity and mortality of COVID-19, and COVID-19 itself causes serious cardiac sequelae. Strategies to minimise the risk of viral transmission to healthcare workers and uninfected cardiac patients while prioritising high quality cardiac care are urgently needed. We conducted a rapid literature appraisal (...) 2 MI (28). Myocardial injury in COVID-19 patients can manifest with ST-elevation in the absence of obstructive coronary artery disease (CAD). Whether this is due to microvascular injury or myocarditis is unclear. To avoid unnecessary coronary angiography during the acute illness, haemodynamically stable patients with COVID-19 and possible MI may be best managed conservatively, with invasive procedures deferred until after COVID-19 recovery. Cardiovascular implications of novel therapies Numerous
Palliative Care Considerations For Patients With CardiovascularDisease Under COVID-19 Palliative Care Considerations For Patients With CardiovascularDisease Under COVID-19 - American College of Cardiology ') Search All Types Search or Menu CBT=cognitive behavioral therapy; IV=intravenous; po=by mouth; SL=sublingually + People with Parkinsonism, Lewy body disease or pre-existing cogwheel rigidity, for whom haloperidol is contraindicated, quetiapine 12.5-25 mg orally up to 4 times daily can (...) to the surge in deaths in most communities. Bereavement support and acknowledgement of both our loss as clinicians, and the family's loss should be routine after a death. Provider Resiliency The cardiovascular care team is immersed on the front lines preparing for the surge of COVID-19 patients or already deeply engaged depending on location. Usual stress and long hours have been superseded by novel adversaries. Clinicians work lacking PPE in a new environment, with risks of COVID-19 illness and mortality
SQC Approval Date: April 24, 2020 Patients with cardiovascularconditions, especially poorly controlled disease, are at higher risk for COVID-19 complications. As such, they should be counseled to avoid situations that would put them at risk for SARS CoV2 exposure. They, along with their physician, should evaluate their workplace and determine if undue risk exists. If so, mitigation strategies should be considered. These include minimizing face-to-face contact between employees, assigning work (...) Syndrome X, Angina, Stable, Heart Defects, Congenital, Dyslipidemias, Geriatrics, Heart Failure, Angiography, Diagnostic Imaging, Pericarditis, Secondary Prevention, Hypertension, Pulmonary, Sleep Apnea Syndromes, Sports, Angina, Stable, Exercise Test, Heart Valve Diseases, Aneurysm, COVID-19, Coronavirus, Coronavirus Infections, Cardiology Magazine, ACC Publications > > Feature | Key Questions on COVID-19 and CardiovascularDisease Heart House 2400 N Street NW Washington, DC 20037 Phone: , ext. 5603
problem of nomenclature that inhibited effective communication became apparent, and this contributed to mistaken diagnoses of POTS. One issue was that even within the expert panel, there was disagreement about whether POTS was a purely cardiovascular and hemodynamic disorder, or one that could be associated with other disorders with systemic (and nonhemodynamic) presentations. Some believed that if a patient had another condition (eg, Ehlers-Danlos syndrome) that they should not be diagnosed with POTS (...) Canadian Cardiovascular Society Position Statement on Postural Orthostatic Tachycardia Syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance Canadian Cardiovascular Society Position Statement on Postural Orthostatic Tachycardia Syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance - Canadian Journal of Cardiology Go search , P357-372, March 01, 2020 Powered By Mendeley Share on Canadian Cardiovascular Society Position Statement on Postural Orthostatic
Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. Bromodomain and extraterminal proteins are epigenetic regulators of gene transcription. Apabetalone is a selective bromodomain and extraterminal protein inhibitor targeting bromodomain 2 and is hypothesized to have potentially favorable effects on pathways related to atherothrombosis. Pooled phase 2 data suggest (...) favorable effects on clinical outcomes.To test whether apabetalone significantly reduces major adverse cardiovascular events.A randomized, double-blind, placebo-controlled trial, conducted at 190 sites in 13 countries. Patients with an acute coronary syndrome in the preceding 7 to 90 days, type 2 diabetes, and low high-density lipoprotein cholesterol levels were eligible for enrollment, which started November 11, 2015, and ended July 4, 2018, with end of follow-up on July 3, 2019.Patients were
Associations of fat and carbohydrate intake with cardiovasculardisease and mortality: prospective cohort study of UK Biobank participants. To investigate the association of macronutrient intake with all cause mortality and cardiovasculardisease (CVD), and the implications for dietary advice.Prospective population based study.UK Biobank.195 658 of the 502 536 participants in UK Biobank completed at least one dietary questionnaire and were included in the analyses. Diet was assessed using
The use of statins in the primary prevention of cardiovasculardisease: an online tool for shared-decision making 2019 www.kce.fgov.be KCE REPORT 324 THE USE OF STATINS IN THE PRIMARY PREVENTION OF CARDIOVASCULARDISEASE: AN ONLINE TOOL FOR SHARED- DECISION MAKING 2019 www.kce.fgov.be KCE REPORT 324 HEALTH TECHNOLOGY ASSESSMENT THE USE OF STATINS IN THE PRIMARY PREVENTION OF CARDIOVASCULARDISEASE: AN ONLINE TOOL FOR SHARED-DECISION MAKING CHRISTOPHE DE MEESTER (KCE), KARIN RONDIA (KCE), THOMAS (...) GOORDEN (LEF), SABINE JANSSENS (BSM), PIETER STEYAERT (TEMPERA), CHRIS DE LAET (KCE), MICHEL ALBERTIJN (TEMPERA), LAURENCE KOHN (KCE) COLOPHON Title: The use of statins in the primary prevention of cardiovasculardisease: an online tool for shared-decision making Authors: Christophe De Meester (KCE), Karin Rondia (KCE), Thomas Goorden (LEF), Sabine Janssens (BSM), Pieter Steyaert (Tempera), Chris De Laet (KCE), Michel Albertijn (Tempera), Laurence Kohn (KCE) Information specialist: Nicolas Fairon (KCE
disease prevention medications at least 80% of the time. The proportion of patients considered adherent increased by a median of 6.9 percentage points (an increase of ≈ 9.9%) The remaining 21 studies used various tools to measure adherence (e.g., objective provider counts or records, self-report) and reported generally favorable results. CardiovascularDisease Risk Conditions A subset of 17 studies evaluated intervention effects on blood pressure control and lipid control. There was a median increase (...) " or "cardiovasculardiseases").mp. 33. ("cerebrovascular disease" or "cerebrovascular diseases" or "cerebrovascular event" or "cerebrovascular events" or "angina" or "coronary disease" or "coronary artery disease" or "ischemia" or "myocardial ischemic preconditioning").mp. 34. ("transient ischemic attack" or "brain hypoxia ischemia" or "myocardial ischemia" or "heart diseases" or "myocardial infarction" or "stroke" or "cerebrovascular disorders" or "basal ganglia cerebrovascular disease").mp. 35. (angina pectoris
Healthy lifestyle and life expectancy free of cancer, cardiovasculardisease, and type 2 diabetes: prospective cohort study. To examine how a healthy lifestyle is related to life expectancy that is free from major chronic diseases.Prospective cohort study.The Nurses' Health Study (1980-2014; n=73 196) and the Health Professionals Follow-Up Study (1986-2014; n=38 366).Five low risk lifestyle factors: never smoking, body mass index 18.5-24.9, moderate to vigorous physical activity (≥30 minutes (...) /day), moderate alcohol intake (women: 5-15 g/day; men 5-30 g/day), and a higher diet quality score (upper 40%).Life expectancy free of diabetes, cardiovasculardiseases, and cancer.The life expectancy free of diabetes, cardiovasculardiseases, and cancer at age 50 was 23.7 years (95% confidence interval 22.6 to 24.7) for women who adopted no low risk lifestyle factors, in contrast to 34.4 years (33.1 to 35.5) for women who adopted four or five low risk factors. At age 50, the life expectancy free